3 results match your criteria: "1825MCPHS University[Affiliation]"
Clinical Response and Cost-Savings Associated With Generic Fluticasone Propionate/Salmeterol Multidose, Dry-Powder Inhaler in Asthma Patients Managed in an Ambulatory Care Practice Setting.
J Pharm Pract
April 2022
Pharmacy Practice, 1825MCPHS University, Boston, MA, USA.
Background: Fluticasone propionate/salmeterol multidose, dry powder inhaler (MDPI) was the first and only authorized generic inhaled corticosteroid/long-acting beta agonist (ICS/LABA) combination inhaler at the time of this study. This offers the potential for significant prescription cost-savings for both patients and accountable care organizations. The objective of the study was to demonstrate patients' clinical response to generic fluticasone propionate/salmeterol MDPI when switched from one of its brand name competitors.
View Article and Find Full Text PDFDexmedetomidine for Facilitating Mechanical Ventilation Extubation in Difficult-to-Wean ICU Patients: Systematic Review and Meta-Analysis of Clinical Trials.
J Intensive Care Med
August 2021
Department of Pharmacy and Critical Care Medicine, Clinical Translational Science Institute, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Article Synopsis
- Dexmedetomidine potentially helps expedite extubation in difficult-to-wean ICU patients, significantly reducing the time to extubation by an average of 11.61 hours.
- There is also a notable decrease in ICU length of stay by about 3.04 days, although it poses an increased risk of hypotension without affecting bradycardia or mortality rates.
- The study suggests that while dexmedetomidine improves certain clinical outcomes, careful monitoring for hypotension is advised during its use in this patient population.
A Retrospective Review of Angiotensin II Use in Adult Patients With Refractory Distributive Shock.
J Intensive Care Med
December 2020
Department of Anesthesia, Critical Care and Pain Medicine, 1859Beth Israel Deaconess Medical Center, Boston, MA, USA.
Purpose: Catecholamines are first-line vasopressors for hemodynamic support in distributive shock but are associated with adverse effects, which may be mitigated with noncatecholamine vasopressors. Angiotensin II (ATII) is a noncatecholamine vasopressor recently approved for the management of distributive shock, but limited data support its clinical utility. The purpose of this study was to describe our institution's usage of ATII including patient outcomes (eg, response to therapy, safety profile).
View Article and Find Full Text PDF